Scientifically, it provides a new perspective for exploring the molecular mechanisms of APL; clinically, serum lipid markers and LDH levels are likely to be used for early diagnosis and prognosis evaluation in APL patients, while the PTK2 gene holds promise as a new therapeutic target. This evidence concerns the gene PTK2 and acute promyelocytic leukemia.